NCT03301220 2026-04-13
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Active not recruiting
Clinical Trials
124 trialsNCT03901963 2026-04-13
AURIGA
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04181827 2026-04-13
CARTITUDE-4
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03652064 2026-04-08
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04162210 2026-03-31
DREAMM-3
GlaxoSmithKline
Phase 3 Active not recruiting
NCT00602641 2026-03-03
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03480360 2026-02-19
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
Phase 3 Active not recruiting
NCT03710603 2026-02-10
Perseus
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT03275285 2026-02-09
IKEMA
Sanofi
Phase 3 Completed
NCT01208662 2026-01-22
DFCI 10-106
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT03246529 2026-01-15
GENESIS
BioLineRx, Ltd.
Phase 3 Active not recruiting
NCT03180736 2025-12-19
EMN14
European Myeloma Network B.V.
Phase 3 Completed
NCT03201965 2025-11-26
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 3 Completed
NCT01169337 2025-11-25
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00114101 2025-11-24
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02252172 2025-10-20
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT04459416 2025-10-20
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
NCT01241708 2025-09-17
(Mel/MelVel)
Hackensack Meridian Health
Phase 3 Completed
NCT02136134 2025-08-29
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT02195479 2025-08-22
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT06956170 2025-06-11
DREAMM 8
GlaxoSmithKline
Phase 3 Active not recruiting
NCT03941860 2025-05-23
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
National Cancer Institute (NCI)
Phase 3 Completed
NCT03158688 2025-05-09
CANDOR
Amgen
Phase 3 Completed
NCT06868667 2025-05-09
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT02076009 2025-05-01
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT03277105 2025-04-29
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT06868654 2025-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT02541383 2025-04-13
Cassiopeia
Intergroupe Francophone du Myelome
Phase 3 Completed
NCT03748953 2025-03-21
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
Takeda
Phase 3 Completed
NCT04484623 2025-03-18
DREAMM 8
GlaxoSmithKline
Phase 3 Active not recruiting
NCT01539083 2025-02-04
VCAT
Janssen Scientific Affairs, LLC
Phase 3 Completed
NCT02990338 2025-01-17
ICARIA-MM
Sanofi
Phase 3 Completed
NCT02181413 2024-11-19
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
Takeda
Phase 3 Completed
NCT04246047 2024-10-24
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT02939287 2024-10-22
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
Rush University Medical Center
Phase 3 Completed
NCT03110562 2024-08-21
BOSTON
Karyopharm Therapeutics Inc
Phase 3 Completed
NCT03859427 2024-08-13
ARROW2
Amgen
Phase 3 Completed
NCT03151811 2024-01-30
OCEAN
Oncopeptides AB
Phase 3 Terminated
NCT04549363 2023-12-13
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
GlaxoSmithKline
Phase 3 Terminated
NCT02312206 2023-11-14
VITAL
Prothena Biosciences Ltd.
Phase 3 Terminated
NCT02312258 2023-09-21
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
Takeda
Phase 3 Completed
NCT00049673 2023-09-13
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Completed
NCT01951885 2023-09-11
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Case Comprehensive Cancer Center
Phase 3 Completed
NCT02755597 2023-08-22
Bellini
AbbVie
Phase 3 Completed
NCT01850524 2023-07-21
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Takeda
Phase 3 Completed
NCT04649060 2023-06-08
LIGHTHOUSE
Oncopeptides AB
Phase 3 Terminated
NCT01734928 2023-06-06
OPTIMISMM
Celgene
Phase 3 Completed
NCT02516696 2023-06-05
BiRd vs Rd
Weill Medical College of Cornell University
Phase 3 Terminated
NCT02726581 2023-03-27
CheckMate 602
Bristol-Myers Squibb
Phase 3 Completed
NCT01564537 2023-03-10
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Takeda
Phase 3 Completed